Ticker > Company >

Kabra Drugs share price

Kabra Drugs Ltd.

BSE: 524322 SECTOR: Pharmaceuticals & Drugs  8.12 K   12   1

19.61
-0.55 (-2.73%)
BSE: 10 Sep 04:01 PM

Price Summary

Today's High

₹ 21

Today's Low

₹ 19.17

52 Week High

₹ 22.77

52 Week Low

₹ 9.14

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

46.49 Cr.

Enterprise Value

45.53 Cr.

No. of Shares

2.37 Cr.

P/E

0

P/B

1.92

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  10.19

CASH

2.67 Cr.

DEBT

1.71 Cr.

Promoter Holding

0 %

EPS (TTM)

₹  -0.44

Sales Growth

0%

ROE

0 %

ROCE

-42.74%

Profit Growth

-117.84 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 YearNA
3 YearNA
5 YearNA

Profit Growth

1 Year-117.84%
3 Year-227.83%
5 Year-219.81%

ROE%

1 Year0%
3 Year0%
5 Year-573.87%

ROCE %

1 Year-42.74%
3 Year-41.1%
5 Year-31.89%

Debt/Equity

-1.1645

Price to Cash Flow

-222.95

Interest Cover Ratio

-1345.1853

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 0.00 0.00
Mar 2025 0.00 0.00
Dec 2024 0.00 0.00
Sep 2024 0.00 0.00
Jun 2024 0.00 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 0 days.

 Limitations

  • The company has shown a poor profit growth of -227.828382074125% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Company has a poor ROCE of -41.1005666666667% over the past 3 years
  • Company has negative cash flow from operations of -0.2085274.
  • The company has a low EBITDA margin of 0% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 0 0 0 0 7.15
Total Expenditure 0.55 0.4 0.54 0.24 7.66
Operating Profit -0.55 -0.4 -0.54 -0.24 -0.51
Other Income 0 0 0 0.64 0.02
Interest 0 0 0 0 0
Depreciation 0 0 0 0.01 0
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.55 -0.4 -0.54 0.39 -0.5
Tax 0 0 0 0 0
Profit After Tax -0.55 -0.4 -0.54 0.39 -0.5
Adjusted EPS (Rs) -1.24 -0.39 -0.53 0.17 -0.21

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 0 0 0 0 0
Total Expenditure 0.05 0.15 0.18 0.34 0.74
Operating Profit -0.05 -0.15 -0.18 -0.34 -0.74
Other Income 0.02 0 0 0.01 0
Interest 0 0 0 0 0
Depreciation 0.03 0.03 0.01 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.06 -0.18 -0.19 -0.34 -0.74
Tax 0 0 0 0 0
Net Profit -0.06 -0.18 -0.19 -0.34 -0.74
Adjusted EPS (Rs.) -0.14 -0.41 -0.42 -0.77 -1.68

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 4.39 4.39 4.39 4.39 4.39
Total Reserves -4.42 -4.6 -4.78 -5.12 -3.31
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0 0 0 0
Current liabilities 1.44 1.61 1.12 1.43 3.49
Total Liabilities 1.41 1.4 0.73 0.7 4.57
Assets
Net Block 0.04 0.01 0 0 0
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0.02 0.02 0.02 0.02 0.02
Other N/C Assets 0 0 0 0 0
Current Assets 1.35 1.37 0.71 0.68 4.55
Total Assets 1.41 1.4 0.73 0.7 4.57
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -0.06 -0.18 -0.19 -0.34 -0.74
Adjustment 0.01 0.03 0.01 0 0
Changes in Assets & Liabilities 0 -0.1 0.04 -0.02 0.53
Tax Paid 0 0 0 0 0
Operating Cash Flow -0.05 -0.25 -0.13 -0.35 -0.21
Investing Cash Flow 0.06 0 0 0 0
Financing Cash Flow -0.02 0.25 0.13 0.36 2.88
Net Cash Flow 0 0 -0.01 0 2.67

Corporate Actions

Investors Details

PARTICULARS Sep 2018% Dec 2018% Mar 2019% Jun 2019% Sep 2019%
promoters 23.88 23.88 23.88 23.88 23.88
ayush kabra 5.06 5.06 5.06 5.06 5.06
kusum kabra 7.87 7.87 7.87 7.87 7.87
shyam kabra 10.95 10.95 10.95 10.95 10.95
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 100.00 100.00 100.00 100.00 100.00
chandraprakash jamnalal k... - 3.97 3.97 1.69 1.69
farahan karim amalani - 1.98 1.98 1.48 1.48
giridhar gupta somisetty - - - - 1.01
himanshu rajendra kumar j... - - - 2.11 2.16
kruti sevanti doshi - - - 2.11 2.11
kuniamuthur nanjappan ana... - 6.53 6.53 2.78 2.78
neha sagar shah - - - 1.05 1.05
priyam samir shah - 3.47 3.47 2.74 2.74
sagar praful shah - - - 1.05 1.05
somisetty malathi latha - - - 1.27 1.34
vijay kumar reddy veeramr... - - - 3.37 3.70
muralidharan.r - 4.53 4.53 1.29 -
gladis menezes - 1.98 1.98 - -
manjula vinod kothari 3.34 1.45 1.45 - -
miral hemantbhai bhoot - 1.98 1.98 - -
praveen kumar saboo - 1.04 1.04 - -
rahul anantrai mehta 4.70 2.05 2.05 - -
rajendrakumar sukhraj jai... - 1.98 1.98 - -
ranjana kanda - 1.98 1.98 - -
ananth kumar teja shree 1.83 - - - -
anupriya sureka 2.06 - - - -
b v chandan yadav 1.80 - - - -
dheeraj ananth kumar 1.85 - - - -
divya kanda 1.16 - - - -
g b bhat 1.61 - - - -
k satish 1.61 - - - -
landmark capital markets ... 1.29 - - - -
m y thulasi mani 1.15 - - - -
manjunath b r 1.06 - - - -
p b pradeep . 2.13 - - - -
ramesh rai 1.37 - - - -
ruchira goyal 1.05 - - - -
sanjaykumar ramabhai pate... 1.46 - - - -
shilpa satish 1.20 - - - -
varsha chugh . 1.29 - - - -
vinay kumar v 1.32 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Kabra Drugs informs about press release 10 Sep, 2:18 PM Kabra Drugs informs about book closure 3 Sep, 5:23 PM Kabra Drugs - Quaterly Results 14 Aug, 6:42 PM Kabra Drugs - Quaterly Results 14 Aug, 6:42 PM Kabra Drugs informs about board meeting 9 Jun, 12:44 PM Kabra Drugs informs about outcome of EGM 2 Jan, 4:44 PM Kabra Drugs informs about outcome of AGM 30 Sep, 12:33 PM Kabra Drugs informs about disclosure 19 Sep, 5:35 PM Kabra Drugs - Quaterly Results 14 Aug, 5:44 PM Kabra Drugs informs about outcome of board meeting 15 Jul, 3:25 PM Kabra Drugs informs about revised unaudited results 6 Mar, 5:16 PM Kabra Drugs informs about voting results of EGM 19 Feb, 5:03 PM Kabra Drugs - Quaterly Results 14 Feb, 4:48 PM Kabra Drugs - Quaterly Results 14 Feb, 4:48 PM Kabra Drugs informs about trading window closure 1 Jan, 12:55 PM Kabra Drugs informs about outcome of board meeting 16 Dec, 11:21 AM Kabra Drugs submits board meeting intimation 26 Aug, 2:48 PM Kabra Drugs informs about board meeting 5 Aug, 10:39 AM Kabra Drugs informs about AGM notice 22 Sep, 2:39 PM Kabra Drugs submits AGM 14 Sep, 3:07 PM Kabra Drugs informs about book closure 8 Sep, 4:25 PM Kabra Drugs informs about annual secretarial compliance report 5 May, 3:03 PM Kabra Drugs informs about compliance certificate 8 Apr, 4:39 PM Kabra Drugs informs about compliance certificate 8 Apr, 3:45 PM Kabra Drugs informs about trading window closure 1 Jan, 12:58 PM Kabra Drugs informs about outcome of board meeting 2 Sep, 5:06 PM Kabra Drugs informs about outcome of the board meeting 3 Jul, 11:18 AM

Kabra Drugs Stock Price Analysis and Quick Research Report. Is Kabra Drugs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Kabra Drugs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Kabra Drugs has a PE ratio of -44.6188850967008 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Kabra Drugs has ROA of -27.9082% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Kabra Drugs has a Current ratio of 1.3038.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Kabra Drugs has a ROE of 0%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Kabra Drugs has a Debt to Equity ratio of -1.1645 which means that the company has low proportion of debt in its capital.

  • Sales growth: Kabra Drugs has reported revenue growth of 0% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Kabra Drugs for the current financial year is 0%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Kabra Drugs is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Kabra Drugs is Rs -0.4395. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Kabra Drugs in Ticker for free. Also, one can get the intrinsic value of Kabra Drugs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Kabra Drugs FAQs

Q1. What is Kabra Drugs share price today?
Ans: The current share price of Kabra Drugs is Rs 19.61.

Q2. What is the market capitalisation of Kabra Drugs?
Ans: Kabra Drugs has a market capitalisation of Rs 46.49109385 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Kabra Drugs?
Ans: The PE ratio of Kabra Drugs is -44.6188850967008 and the P/B ratio of Kabra Drugs is 1.92471904598322, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Kabra Drugs share?
Ans: The 52-week high share price of Kabra Drugs is Rs 22.77, and the 52-week low share price of Kabra Drugs is Rs 9.14.

Q5. Does Kabra Drugs pay dividends?
Ans: Currently, Kabra Drugs does not pay dividends. Dividend yield of Kabra Drugs is around 0%.

Q6. What are the face value and book value of Kabra Drugs shares?
Ans: The face value of Kabra Drugs shares is Rs 10, while the book value per share of Kabra Drugs is around Rs 10.1885. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Kabra Drugs?
Ans: Kabra Drugs has a total debt of Rs 1.7084503 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Kabra Drugs?
Ans: The ROE of Kabra Drugs is 0% and ROCE of Kabra Drugs is -42.7374%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Kabra Drugs a good buy for the long term?
Ans: The Kabra Drugs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Kabra Drugs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Kabra Drugs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Kabra Drugs’s financials?
Ans: You can review Kabra Drugs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Kabra Drugs
X